Small cell lung cancer, or SCLC, is aggressive, lethal and particularly cruel because chemotherapy initially works so well. But within just a few months, SCLC becomes resistant to drugs and dashes ...
The early-stage clinical trial marks the first U.S. testing of Alveltamig, an immunotherapy designed to help the immune ...
ZL-1310, targeting DLL3, shows early antitumor activity in extensive-stage SCLC, with 74% of patients experiencing tumor shrinkage or disappearance. The FDA's fast track designation for ZL-1310 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback